2/25
11:26 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell [Yahoo! Finance]
2/25
11:05 am
lgvn
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Medium
Report
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
2/13
04:41 pm
lgvn
Longeveron appoints new CEO [Seeking Alpha]
Low
Report
Longeveron appoints new CEO [Seeking Alpha]
2/13
04:30 pm
lgvn
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Low
Report
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
2/5
09:15 am
lgvn
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Medium
Report
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
1/29
09:15 am
lgvn
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Medium
Report
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
1/26
09:23 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) [Yahoo! Finance]
1/26
09:15 am
lgvn
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Medium
Report
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
12/29
09:37 am
lgvn
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 [Yahoo! Finance]
Medium
Report
Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 [Yahoo! Finance]
12/29
09:15 am
lgvn
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Low
Report
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
12/17
09:15 am
lgvn
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Low
Report
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy